The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment

Hormone and Metabolic Research

Volumn 28, Issue 10, 1996, Pages 562-564

  Hill, M ^a   Petrik R ^a   Hampl, R ^a   Starka L ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; EPITESTOSTERONE; FINASTERIDE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY;

EID: 0029832371     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979853     Document Type: Article

References (13)

1. Bartsch, W., M. Krieg, H. Beecker, J. Mohrmann, K. D. Voigt: Endogenous androgen levels in epithelium and strom aof human benign prostatic hyperplasia an dnormal prostate. Acta Endocrinol. 100: 634-640 (1982)
2. Bičíková, M., R. Hampl, M. Hill, L. Stárka. Inhibition of steroid 17α-hydroxylase and C17,20-lyase in the human testis by epitestosterone. J. Steroid Biochem. Mol. Biol. 46: 515-518 (1993)
3. Bílek, R., R. Hampl, Z. Putz, L. Stárka: Radioimmunoassay of epitestosterone; methodology, thermodynamic aspects and applications. J. Steroid Biochem. 28: 723-729 (1987)
4. Bolton, N. J., R. Lahtonen, G. L. Hammond, R. Vihko: Distribution and concentrations of androgens in epithelial and stromal compartments of the human benign hypertrophic prostate. J. Endocrinol. 90: 125-131 (1981)
5. Hammond, G. L.: Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J. Endocrinol. 78: 7-19 (1978)
6. Hill, M., R. Hampl, R. Petřik, L. Stárka: Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue. Prostate 28: 347-351 (1996)
7. Krieg, M., R. Nass, S. Tunn: Effect of ageing on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrin. Metab. 77: 375-381 (1993)
8. Lapcik, O., A. Perheentupa, M. Bicikova, I. Huhtaniemi, R. Hampl, L. Stárka: The effect of epitestosterone on gonadotrophin synthesis and secretion. J. Endocrinol. 143: 353-358 (1994)
9. McConnell, J. D., J. D. Wilson, F. W. George, J. Geller, F. Pappas, E. Stoner: Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrin. Metab. 74: 505-508 (1992)
10. Nuck, B. A., A. W. Lucky: Epitestosterone: a potential new antiandrogen. J. Invest. Dermatol. 89: 209-211 (1987)
11. Schröder, F. H.: 5α-Reductase inhibitors and prostatic disease. Clin. Endocrinol. 41: 139-147 (1994)
12. Stárka, L., M. Bičíková, R. Hampl: Epitestosterone - an endogenous antiandrogen? J. Steroid Biochem. 33: 1019-1021 (1989)
13. Stoner, E.: 5α-Reductase inhibitors for the treatment of benign prostatic hyperplasia. Recent Progr. Hormone Res. 49: 285-292 (1994)